Sage Journals: Discover world-class research

Abstract

The aim of this study is to evaluate the correlations of peak oxygen uptake (VO2peak) with lung mechanics, radiographic abnormalities, and quality of life (QoL) in adults with post-tuberculosis lung disease (PTLD). This is a cross-sectional study in which 60 adults with PTLD underwent a cardiopulmonary exercise test (CPET). Additionally, the following assessments were performed: spirometry, impulse oscillometry (IOS), chest X-ray (CXR), and QoL using the WHOQOL-BREF. The mean peak oxygen uptake (VO_2peak) was 16.1 ± 6.8 ml/kg/min. There were positive correlations between VO_2peak and several parameters, including height, physical–WHOQOL-BREF, and forced vital capacity (FVC). There were negative correlations between VO_2peak and several parameters, including age, heterogeneity of resistance between 5 and 20 Hz, frequency response (Fres), and reactance-area. In IOS, patients with small airway disease (SAD) had a lower VO_2peak. Regarding CXR, only cavitation and nodular opacities were associated with a lower VO_2peak. In multivariate analysis, FVC, age, male sex, and Fres explained 65.2% of the variability in VO_2peak. In conclusion, there is a relationship between VO_2peak and lung mechanics in patients with PTLD. In these patients, IOS is able to detect more pulmonary mechanical alterations than spirometry, including those reflecting SAD. Thus, the use of both CPET and IOS may aid in the monitoring of patients with PTLD.

Keywords

post-tuberculosis lung disease exercise lung function chest X-ray quality of life

Introduction

Post-tuberculosis lung disease (PTLD) is emerging as a disease of great interest due to increased tuberculosis (TB) survival rates driven by advances in anti-TB therapy and the expansion of public health systems.^1,2 As the number of TB survivors rises, the long-term repercussions have garnered greater attention due to their profound clinical and socioeconomic impacts.² In 2020, it was estimated that there were 155 million TB survivors still alive worldwide^,3 and the prevalence of PTLD is estimated to range from 18% to 87%.⁴ The estimated disability-adjusted life-years (DALYs) is 12.1, with 28% covering 15 or more years after the initial TB episode.⁵ Furthermore, PTLD patients, even after successful treatment, have a 3.76 times higher all-cause mortality rate compared to the general population.⁶ The variability in PTLD presentation depends on several factors, including the severity of the initial infection, the extent of lung damage, the effectiveness of therapy, and the presence of comorbidities.^1,2,7

The extent of lung damage in PTLD is vast and depends on the individual’s immune response, which may vary due to genetic differences and external environmental factors such as smoking, pollution, and concomitant infections.⁸ About 96% of patients present with residual lung damage on chest X-ray (CXR) after anti-TB chemotherapy.⁹ A major obstacle to understanding PTLD has been its heterogeneity, as the spectrum of radiological manifestations ranges from tracheobronchial stenosis to bronchiectasis, nodular opacities, pulmonary fibrosis, cavitation, pleural involvement, and small airway dysfunction (SAD).^2,7,10 One of the main imaging findings in PTLD is bronchiectasis, which may also develop secondary to the destruction of adjacent parenchyma and fibrosis.¹¹ Although most cavities heal and close after anti-TB chemotherapy, some persist beyond treatment and may undergo secondary colonization by pathogens such as Aspergillus fumigatus.⁷

Residual lung damage following pulmonary TB (PTB) treatment contributes to pulmonary function decline. The heterogeneity of lung damage in PTLD can manifest as either obstructive or restrictive patterns,¹ and 10% of patients lose more than half of their lung function.¹² These residual damages can be detected through spirometry, which is a useful tool for measuring lung function.¹³ However, since spirometry depends on patient effort and mental tenacity, it underestimates the extent of lung damage when compared to other traditional pulmonary function tests (PFTs), such as body plethysmography and diffusion capacity for carbon monoxide (DLco) measurement.¹⁴ Additionally, spirometry is unable to reliably assess SAD, which appears to be common in these patients.^2,15 In this sense, impulse oscillometry (IOS) has proven to be a sensitive tool for assessing small airway function in various pulmonary conditions, including COPD, by employing low-frequency waves to measure small airway resistance.¹⁶

In patients with PTLD, not only are persistent respiratory symptoms common, but also a reduction in exercise capacity.¹⁷ In this context, the cardiopulmonary exercise test (CPET) is considered the gold standard for assessing cardiorespiratory fitness (CRF), providing a comprehensive assessment of the integrative responses to exercise.¹⁸ Using CPET in PTLD, a recent study demonstrated weak correlations between peak oxygen uptake (VO_2peak) and traditional PFTs, including spirometry, body plethysmography, and DLco measurement.¹⁹ However, these authors did not assess SAD using IOS, and SAD may be a contributor to exercise performance in patients with PTLD, although it has never been evaluated in this patient population. It is likely that the relationship between pathophysiology and predictors of exercise capacity in PTLD is more complex than previously thought, possibly driven by both the multicompartmental involvement of lung destruction during PTB and the inconsistency in the presentation of PTLD.¹⁹

PTLD can have a profound impact on the quality of life (QoL) of affected individuals, impairing lung function and reducing exercise capacity.⁷ Although traditional PFTs—particularly spirometry—are commonly used as diagnostic tools to assess respiratory impairment after PTB treatment, they fail to capture the complex spectrum of PTLD.²⁰ Furthermore, the prevalence of radiological findings in PTLD is highly variable, and the relationship between radiological findings and functional impairment has not been well studied.²⁰ Many studies assessing PTLD burden have used traditional PFTs as surrogate measures of exercise capacity, without considering oxygen consumption and SAD.^1,13,14 We hypothesized that there is a relationship between peak oxygen uptake (VO_2peak), SAD, and structural damage in PTLD. Thus, this study aimed to evaluate the correlations between oxygen consumption during exercise and resting lung mechanics, radiographic abnormalities, and QoL in adults with PTLD.

Materials and methods

Participants

Between March and December 2024, we conducted a cross-sectional study with patients aged ≥18 years diagnosed with PTLD at the Piquet Carneiro University Policlinic of the State University of Rio de Janeiro, Rio de Janeiro, Brazil. Since our institution has a dedicated PTLD outpatient clinic, these patients were approached sequentially as they were seen and invited to participate in the study. We defined PTLD as a chronic respiratory abnormality, with or without symptoms, attributed at least in part to previous pulmonary TB.²¹ In this study, we defined pulmonary sequelae as any abnormalities detected in one or more of the following assessments: persistent clinical symptoms, CXR, and spirometry.²² Patients who had completed PTB treatment within the past 3 years and who had been treated for drug-susceptible PTB with bacteriological cure were included. We applied the following exclusion criteria: the presence of pulmonary comorbidities unrelated to PTLD; any absolute contraindications to CPET (acute myocardial infarction within 3–5 days, unstable angina, uncontrolled arrhythmia, syncope, active endocarditis, acute myocarditis or pericarditis, severe aortic stenosis, uncontrolled heart failure, suspected aortic aneurysm, and arterial desaturation at rest on room air <85%)²³; and any inability to perform CPET. The Research Ethics Committee of the State University of Rio de Janeiro, Rio de Janeiro, Brazil, approved the protocol under CAAE-70493823.5.0000.5259, and all patients signed the consent form.

Instruments and measurements

Measurements were conducted in the following order: QoL assessment using the World Health Organization Quality of Life (WHOQOL-BREF) questionnaire, assessment of dyspnea severity using the modified Medical Research Council scale (mMRC), assessment of pulmonary function starting with IOS followed by spirometry and finally, the CPET. In addition, the patients were asked to bring their most recent CXR that had been taken within the previous 3 months, and 54 of them did so. The CXRs were read by a pulmonologist (AJL, with 30 years of experience in thoracic radiology). The median time between CXRs and completion of TB treatment was 22 (19–24) months, while the mean time between CXRs and the date of the research visit was 62 ± 11 days.

The WHOQOL-BREF is a self-administered questionnaire consisting of 26 questions divided into four domains: physical, psychological, social relationships, and environment. A score can be obtained for each domain. All scores follow an ascending and positive scale, where higher scores indicate greater QoL. On a 0–100 scale, 0 represents an extremely poor QoL, while 100 denotes an exceptionally good QoL.²⁴

The mMRC dyspnea scale consists of five items, and participants select the one that best represents how dyspnea limits their activities of daily living. Participants report their subjective degree of dyspnea by choosing a value from 0 to 4, with higher values indicating more intense dyspnea. The mMRC dyspnea scale has demonstrated satisfactory reliability and validity.²⁵

To assess SAD, we performed IOS using the Quark i2m (Cosmed, Rome, Italy) device, following previous recommendations.²⁶ We assessed the following resistive and reactive parameters: respiratory system resistance (Rrs) at 5 Hz (R5) and 20 Hz (R20); mean resistance between 5 and 20 Hz (Rm); heterogeneity of resistance between 5 and 20 Hz (R5–R20); frequency response (Fres); respiratory system reactance (Xrs) at 5 Hz (X5) and 20 Hz (X20); and reactance area (Ax). Abnormal values were defined as Fres >12 Hz and Ax ≥8.66 cm H₂O/L/s.^27,28 We performed spirometry with a Vitatrace VT 130 SL device (Codax Ltda, Rio de Janeiro, Brazil), following previous standardizations.²⁹ The Brazilian predicted equations were used to interpret the spirometry.³⁰ In the spirometry test, a restrictive pattern was suggested by a forced vital capacity (FVC) < 80% predicted (%pred), while an obstructive pattern was defined by a forced expiratory volume in one second (FEV₁)/FVC <70%.³¹

CPET was conducted according to prior recommendations¹⁶ using a breath-by-breath system on a cycle ergometer connected to the FitMate™ (Cosmed, Rome, Italy) and an ergometer bicycle (Ergoselect 4 SN, Ergoline GmbH, Bitz, Germany). The FitMate™ employs a new sampling technology using a representative small sample of the expired volume in a miniaturized dynamic mixing chamber. This device uses a turbine flowmeter to measure ventilation and a galvanic fuel cell oxygen sensor to analyze the fraction of expired oxygen. The FitMate™ is not equipped with a CO₂ analyzer; instead, it has a software that ramps up the respiratory exchange ratio between 0.8 and 1.2 based on increases in heart rate (HR).³² Participants pedaled at a rate of 55–65 revolutions per minute (RPM) and the test was stopped if the cadence fell below 40 rpm; the workload was increased by 10 W/min until maximum tolerance was reached. VO_2peak was considered the highest VO₂ volume averaged over a 20–30 s period achieved at presumed maximal effort.³³ The exercise was terminated when participants developed marked dyspnea (Modified Borg scale between 9 and 10) or muscle fatigue and reached exhaustion. The following criteria were used to establish a maximum effort: maximum HR >90% of age predicted (220 - age) or a plateauing of VO₂.³⁴

Statistical analysis

The normality of data distribution was verified using the Shapiro–Wilk test. The criterion for determining significance was the 5% level. Statistical analysis was performed using the SPSS software, version 26 (IBM Corporation, Armonk, NY, USA). The association between VO_2peak and numerical variables was analyzed using Spearman’s correlation coefficient. The values were interpreted according to the following cut-off points: <0.10 = insignificant correlation; 0.10–0.39 = weak correlation; 0.40–0.69 = moderate correlation; 0.70–0.89 = strong correlation; and 0.90–1.00 = very strong correlation.³⁵ The association between VO_2peak and categorical variables was analyzed using the Student’s t-test for independent samples or one-way ANOVA. Tukey’s multiple comparison test was applied to identify which categories differed significantly from each other. The association between smoking and categorical variables was analyzed using the Fisher’s exact test. We employed multiple linear regression (MLR) using the stepwise forward selection method to identify independent variables that explained the variability of VO_2peak.

To provide context for interpreting the null findings, a post hoc power analysis was performed using G*Power 3.1.9.7 software based on the actual sample size (n = 60) and the observed correlations between the main outcome (VO_2peak) and the other studied variables. Based on a priori type-I error α = 0.05 (two-tailed), a complete-case analysis showed that the observed significant effects were detected with a power ranging from 99 to 64%, showing the adequacy of the studied sample size to obtain significant results.³⁶

Results

Of the 66 patients evaluated for inclusion in the study, 6 were excluded for the following reasons: 3 due to contraindications to CPET (unstable angina, uncontrolled heart failure, and arterial desaturation at rest); 2 due to orthopedic impairments in the lower limbs rendering CPET impossible; and 1 due to a history of asthma. Of the 60 participants included in the study, 34 (56.7%) were women. The mean age was 55.1 ± 14.1 years, while the median time since the end of TB treatment was 24 (20–27) months. A history of smoking was reported by 29 (48.3%) participants, with a median smoking load of 25 (9–39) pack-years. While 46 (76.7%) participants had an mMRC score of 0-1, only 14 (23.3%) had an mMRC score of 2–4. Regarding QoL as assessed by the WHOQOL-BREF questionnaire, the worst-performing domains were physical and environment. Table 1 shows anthropometric data, clinical characteristics, lifestyle, comorbidities, dyspnea severity, and QoL.

Table 1.

Anthropometric data, clinical characteristics, lifestyle, comorbidities, degree of dyspnea, and quality of life in the total sample (n = 60).

Variable	Values
Anthropometry
Age (years)	55.1 ± 14.1
Weight (kg)	64 ± 14.5
Height (m²)	1.66 ± 0.09
BMI (kg/m²)	23.2 ± 4.2
Clinical characteristics/lifestyle
Time since end of treatment (months)	24 (20–27)
Smoking history	29 (48.3%)
Habitual physical activity	24 (40%)
Chest physiotherapy	5 (8.3%)
Comorbidities
Hypertension	21 (35%)
Diabetes	11 (18.3%)
Chronic heart disease	4 (6.7%)
HIV status	2 (3.3%)
mMRC scale
0	12 (20%)
1	34 (56.7%)
2	9 (15%)
3	4 (6.7%)
4	1 (1.7%)
WHOQOL-BREF questionnaire
Physical	57.6 ± 17.5
Psychological	67.8 ± 15.2
Social relationships	68.7 ± 14.2
Environment	56.2 ± 13.8

Note: Data are presented as median (interquartile range) or number (%).

BMI: body mass index; mMRC: modified medical resource council scale; WHOQOL: world health organization quality of Life.

In spirometry, an obstructive pattern, a restrictive pattern, and a normal pattern were diagnosed in 24 (40%), 14 (23.3%), and 22 (36.7%) participants, respectively. In IOS, 49 (81.7%) participants presented an abnormal test, with SAD diagnosed in 31 (51.7%) participants. In CXR assessment (n = 54), the most frequent findings were: bronchiectasis (n = 27, 50%), nodular opacities (n = 27, 50%), and pulmonary fibrosis (n = 26, 48.1%). Table 2 shows pulmonary function data and radiographic abnormalities.

Table 2.

Pulmonary function, radiographic abnormalities, and cardiopulmonary performance to exercise in the total sample.

Variable	Values
Spirometry (n = 60)
FVC (% predicted)	75.8 ± 21.2
FEV₁ (% predicted)	70.9 ± 27.4
FEV₁/FVC (%)	74.8 ± 16.3
FEF_25–75% (% predicted)	54.2 (28–98)
Impulse oscillometry (n = 60)
Rm (cm H₂O/L/s)	6.1 (6.1–7.1)
R5 (cm H₂O/L/s)	6.5 (5.4–8.3)
R20 (cm H₂O/L/s)	5.8 (4.8–7)
R5-R20 (cm H₂O/L/s)	0.53 (0.14–2.3)
Fres (Hz)	6 (4.7–7.5)
X5 (cm H₂O/L/s)	−2.7 (−4.2–-1.7)
X20 (cm H₂O/L/s)	−0.22 (−1.6–0.28)
Ax (cm H₂O/L/s)	17.1 (6.9–30)
FitMate™ testing (n = 60)
VO_2peak (ml/kg/min)	16.1 ± 6.8
VE_peak (L/min)	41 ± 18.6
End of test HR (pulse/min)	135 ± 28
End of test RR (breaths/min)	38.1 ± 8.3
FeO₂ (%)	17.7 ± 0.6
Total time (min)	4.5 (3.6–7.5)
Peak workload (W)	66.3 ± 26.8
Chest X-ray (n = 54)
Bronchiectasis	27 (50%)
Nodular opacities	27 (50%)
Pulmonary fibrosis	26 (48.1%)
Pulmonary cavitation	12 (22.2%)
Small airway disease	9 (16.7%)
Emphysema	14 (25.9%)
Pleural involvement	14 (25.9%)
Others	37 (68.5%)

Note: Data are presented as median (interquartile range) or number (%).

FVC: forced vital capacity; FEV₁: forced expiratory volume in the 1^st sec; FEF_25–75%: forced expiratory flow during the middle half of the FVC maneuver; Rm: mean resistance between 5 and 20 Hz; R5: respiratory system resistance at 5 Hz; R20: respiratory system resistance at 20 Hz; R5-R20: heterogeneity of resistance between 5 and 20 Hz; Fres: frequency response; X5: respiratory system reactance at 5 Hz; R20: respiratory system reactance at 20 Hz; Ax: reactance-area; VO_2peak: peak oxygen uptake; VE_peak: peak minute ventilation, HR: heart rate; RR: respiratory rate; FeO₂: expired O₂ fraction.

Regarding CPET, all participants reached the limit of exercise tolerance according to the established criteria. The total time and peak workload values were 4.5 (3.6–7.5) min and 66.3 ± 26.8 W, respectively. The mean VO_2peak was 16.1 ± 6.8 ml/kg/min (Table 2). Table 3 and Figure 1 show correlations of VO_2peak with clinical characteristics, QoL, and lung function. There were significant positive correlations between VO_2peak and the following parameters: height, physical–WHOQOL-BREF, FVC, FEV₁, FEV₁/FVC, forced expiratory flow during the middle half of the FVC maneuver, X5, X20, peak minute ventilation, end of test HR, total time, and peak workload. There were significant negative correlations between VO_2peak and the following parameters: age, R5, R5–R20, Fres, and Ax. Male participants had a higher VO_2peak than females [18.3 ± 7.8 versus 14.5 ± 5.3 ml/kg/min, p = 0.038]. Participants with a history of hypertension had a lower VO_2peak than those without [13.4 ± 4.3 versus 17.6 ± 7.4 ml/kg/min, p = 0.007]. Participants with mMRC 0–1 had a higher VO_2peak than those with mMRC 2–4 [17.4 ± 6.9 versus 12 ± 4.5 ml/kg/min, p = 0.008]. In spirometry, participants with a normal pattern, a restrictive pattern, and an obstructive pattern showed significant differences in VO_2peak [19.7 ± 6.7 versus 16.5 ± 5.9 versus 12.7 ± 5.6 ml/kg/min, p = 0.001]. In IOS, participants with SAD had a lower VO_2peak than those without SAD [12.8 ± 5.1 versus 19.7 ± 6.5 ml/kg/min, p < 0.0001]. Regarding CXR, only two imaging findings were associated with a lower VO_2peak: pulmonary cavitation [11 ± 5.1 versus 17.7 ± 6.4 ml/kg/min, p = 0.001] and nodular opacities [14.1 ± 5 versus 18.3 ± 7.5 ml/kg/min, p = 0.016].

Table 3.

Spearman’s correlation coefficients between peak oxygen uptake, clinical characteristics, quality of life, and pulmonary function.

Variable	r _s	P-value
Age	−0.452	0.0002
Weight	0.080	0.54
Height	0.343	0.007
BMI	−0.144	0.27
Time since end of treatment	−0.188	0.14
Smoking load	−0.046	0.81
Physical–WHOQOL-BREF	0.275	0.033
Psychological–WHOQOL-BREF	0.060	0.65
Social relationships–WHOQOL-BREF	0.187	0.15
Environment–WHOQOL-BREF	0.028	0.83
FVC	0.603	<0.0001
FEV₁	0.570	<0.0001
FEV₁/FVC	0.294	0.024
FEF_25–75%	0.450	0.0003
Rm	−0.230	0.080
R5	−0.338	0.008
R20	−0.099	0.46
R5-R20	−0.466	0.0001
Fres	−0.675	<0.0001
X5	0.589	<0.0001
X20	0.462	0.0002
Ax	−0.647	<0.0001
VE_peak	0.866	<0.0001
End of test HR	0.453	0.0002
End of test RR	−0.154	0.24
FeO₂	−0.009	0.94
Total time	0.689	<0.0001
Peak workload	0.568	<0.0001

BMI: body mass index; WHOQOL: World Health Organization quality of life; FVC: forced vital capacity; FEV₁: forced expiratory volume in the 1^st sec; FEF_25–75%: forced expiratory flow during the middle half of the FVC maneuver; Rm: mean resistance between 5 and 20 Hz; R5: respiratory system resistance at 5 Hz; R20: respiratory system resistance at 20 Hz; R5–R20: heterogeneity of resistance between 5 and 20 Hz; Fres: frequency response; X5: respiratory system reactance at 5 Hz; R20: respiratory system reactance at 20 Hz; Ax: reactance-area.

Figure 1.

Relationships of the peak oxygen uptake (VO_2peak) with forced vital capacity (FVC, r_s = 0.603, p < 0.0001) (A), age (r_s = −0.452, p = 0.0002) (B), and frequency response (Fres, r_s = −0.675, p < 0.0001) (C).

Among participants with a history of smoking, 15 (51.7%) had an obstructive pattern and 14 (48.3%) had a non-obstructive pattern (p = 0.89). No significant difference in VO_2peak was found between participants with and without a history of smoking [14.9 ± 5.8 versus 17.3 ± 7.4 ml/kg/min, p = 0.16].

In MLR for VO_2peak, the only independently predictive variables were FVC, age, male sex, and Fres, explaining 65% of its variability (Table 4).

Table 4.

Multiple linear regression for the peak oxygen uptake using clinical characteristics, quality of life, and pulmonary function.

Outcome variable	Independent variables	B	SEB	p-value	R	Adjusted R²
VO_2peak	Constant	12.612	3.223	0.0003
	FVC	0.179	0.027	<0.0001	0.572	0.313
	Age	−0.184	0.044	0.0001	0.743	0.533
	Male	4.431	1.128	0.0003	0.811	0.636
	Fres	−0.260	0.140	0.083	0.824	0.652

B: regression coefficient; SEB: standard error of the regression coefficient; R: correlation coefficient; R²: determination coefficient; FVC: forced vital capacity; Fres: frequency response.

Discussion

There is still much to be discovered, as PTLD is a developing field, with few studies. The main findings of this study indicate that patients with PTLD exhibit a low VO_2peak. In these patients, the lower the VO_2peak, the greater the abnormalities observed in both IOS and spirometry, although IOS is able to detect more alterations in lung mechanics than spirometry. In addition, a lower VO_2peak is associated with the presence of pulmonary cavitation or nodular opacities on the CXR. However, the correlation between VO_2peak and QoL is weak or insignificant. To our knowledge, this is the first study to evaluate the relationship between CPET and lung mechanics using IOS, aiming to assess small airway behavior.

CRF is considered a vital sign in assessing cardiovascular health, and the gold standard for expressing CRF is the VO_2peak. Using a simple, low-cost, and user-friendly cycle ergometer, we could demonstrate changes in VO_2peak in adults with PTLD. Indeed, the VO_2peak measured in this cohort (16.1 ± 6.8 ml/kg/min) was significantly below what is considered normal (35–50 ml/kg/min) for a sedentary adult.¹⁹ In the Brazilian population, Dourado et al.³⁷ recently showed that the minimum VO_2peak value for good performance is 33 ml/kg/min for men and 22 ml/kg/min for women. The mean VO_2peak observed in our study was notably lower than that reported by Curry et al.¹⁹ in PTLD patients (24.3 ± 5.3 ml/kg/min), which may be at least partially explained by the high heterogeneity of PTLD presentations. Persistent inflammation and dysregulated wound-healing responses in the lungs lead to progressive scar tissue accumulation, potentially impairing exercise capacity.⁶ Recent studies indicate that a decrease in pro-inflammatory vascular cell adhesion molecule-1 and an increase in pro-fibrotic collagen 1a are associated with better exercise capacity outcomes after PTB treatment.^1,38 It is worth noting that predicting work rate increments that will result in a CPET period of approximately 8 to 12 min in patients with chronic lung disease is still an open question.³⁹ Assuming an average increase in VO₂ of 10 mL·W⁻¹·min⁻¹ and an assumption about the kinetic lag between the increase in exercise intensity and the VO₂ response, work rate increments should be calculated on an individual basis.^18,39 Because our CPET device does not allow for incremental adjustments and our patients have a mean age >40 years, we used 10 W/min until symptom limitation based on preliminary studies.⁴⁰ It is also important to note the low median (IQR) for exercise duration in our sample, which may be at least partially due to the low performance caused by PTLD.

Regarding pulmonary function at rest, the predominant spirometric pattern in our sample was obstructive, which is in line with findings from another Brazilian cohort evaluated by Silva et al.⁴¹ Notably, COPD is four times more common in individuals with previous PTB, and previous TB is associated with an obstructive pattern, and should be considered a potentially significant cause of obstructive diseases.⁴² In fact, smoking is strongly associated with an increased risk of developing PTB, both in developing and progressing the disease.⁴³ However, in our sample, no association was found between a history of smoking and an obstructive pattern or worse VO_2peak, suggesting that factors other than smoking influence airflow limitation (e.g., chronic residual airway narrowing, peribronchial fibrosis, or bronchial hyperresponsiveness) and worse exercise capacity in patients with PTDL (e.g., loss of parenchymal tissue).^44,45 Importantly, while more than 80% of our sample showed alterations in IOS, only about 60% had alterations in spirometry, highlighting the higher accuracy of IOS and the importance of incorporating this technique into clinical practice when assessing PTLD patients. Additionally, patients with SAD diagnosed with IOS exhibited lower VO_2peak when compared to those without SAD, suggesting that SAD may serve as a marker of poorer CRF in this population. Correlations between VO_2peak and IOS parameters were stronger than those between VO_2peak and spirometry parameters.

In the multivariate analysis, only two pulmonary function variables were included in our explanatory model for VO_2peak: FVC and Fres. FVC reflects the healing process that lungs go through during and after anti-TB treatment, where structural damage leads to excessive collagen deposition.⁴⁵ Conversely, Fres—a marker of SAD corresponding to the equilibrium point where X₅ crosses the horizontal frequency axis⁴⁶—may indicate incipient obstruction in PTLD patients, driven both by inflammation and immune factors that induce small airway hyperresponsiveness.⁴⁵ Similar to our findings, Curry et al.¹⁹ observed that, although statistically significant, the correlations between any lung function patterns — whether measured by spirometry, DLco, or body plethysmography — and VO_2peak were weak. In their study, only the correlation coefficient for FVC exceeded 0.50, and their multivariable model for VO_2peak had an adjusted R² value of just 0.310. This once again highlights the importance of assessing SAD in PTLD patients, as it partially explains their CRF.

In our study, the most frequent radiological findings were bronchiectasis, nodular opacities, and pulmonary fibrosis, which is not surprising since these are described as common in PTLD patients.^2,7 However, we only observed correlations between VO_2peak and pulmonary cavitation, and to a lesser extent, nodular opacities. Pulmonary cavitation involves lung tissue obliteration and the formation of gas-filled cavities.¹ In general, declining pulmonary function tends to be associated with PTLD severity, as there is a significant correlation between increased cavitary volume and decreased FEV₁ in PTLD patients.⁴⁷ Consistent with our findings, Singh et al.⁴⁸ reported that patients with pulmonary cavitation may be at higher risk for progressive declines in exercise capacity. It is worth noting that chest computed tomography (CT) has been shown to be much more sensitive than CXR for detecting abnormalities in patients with PTLD, although it is unlikely that access to chest CT will be available in low- and middle-income countries for routine evaluation of patients after TB treatment.⁴⁹

PTLD can have a profound impact on patients’ QoL, including physical, social, and psychological dimensions.¹¹ Similar to the study by Kodical et al.,⁵⁰ who used the WHOQOL-BREF questionnaire on patients still undergoing treatment for TB, we observed low scores across all assessed domains, indicating impaired QoL even after completing anti-TB therapy. PTLD can isolate individuals from their communities due to the social stigma associated with TB, and disrupt social and occupational roles, leading to unemployment, financial hardship, and reduced social participation.¹³ Interestingly, we observed weak or insignificant correlations between VO_2peak and the domains of the WHOQOL-BREF questionnaire, which indicates that an individual’s perception of their QoL does not necessarily limit their objectively measured exercise capacity. From a practical perspective, this underscores the importance of exploring rehabilitative strategies for these patients, regardless of QoL reported in this population. Of note, the WHOQOL-BREF questionnaire has been widely used in several studies to assess the impact of TB and its treatment,^50–52 as it is important to address all health domains to achieve better QoL.⁵⁰ Interestingly, we observed an association between hypertension and low VO_2peak, which, although previously described,⁵³ has not yet been elucidated pathophysiologically, but suggests a possible benefit of blood pressure control in these individuals.

The strength of this study is that it assessed SAD using IOS and its correlation with the gold standard measure for measuring functional capacity to exertion—VO_2peak. However, several limitations should be noted. First, this is a cross-sectional study and we evaluated data from a single center. This makes it difficult to generalize our results. Second, we did not use percentages of predicted values to calculate VO_2peak; however, the available Brazilian equations for VO_2peak used small samples from specific locations in the country,^34,54 included predominantly young adults,⁵⁴ and differ from international equations,⁵⁵ perhaps due to the statistical methods used. Third, although the participants reached the limit of exercise tolerance, we used a protocol of 10 W/min for all participants, which may have influenced the VO_2peak measurement and exercise time. In fact, it is recommended that a protocol be adapted to the individual characteristics of patients because of differences in age, sex, body size, lung disease, and physical activity level.³⁹ Fourth, we did not assess DLco or body plethysmography, which could have strengthened our results in terms of correlation with CRF. Finally, we did not assess the extent of the disease on CXR, which may have hindered the detection of correlations between radiographic abnormalities and VO_2peak. Here, we highlight the scoring system proposed by Báez-Saldaña et al.⁵⁶ to measure the extent of radiographic abnormalities in patients with PTLD, although it does not take into account the impact of specific lesions caused by TB. Despite these limitations, our findings could serve as a starting point for better understanding reduced exercise capacity in PTLD patients, especially if applied in randomized controlled trials to follow up this patient population and evaluate the effects of rehabilitation.

Conclusion

Our results show that patients with PTLD present a low VO_2peak. There is a relationship between VO_2peak and lung mechanics. In these patients, IOS is capable of capturing more changes in lung mechanics than spirometry, including those reflecting SAD. There is a relationship between VO_2peak and radiographic abnormalities, especially with pulmonary cavitation and nodular opacities. However, the relationship between VO_2peak and QoL is virtually nonexistent. With this in mind, the use of both CPET and IOS can aid in the monitoring of patients with PTLD, including assessing the impact of interventions.

Footnotes

Acknowledgements

The authors would like to thank the entire team of professionals at the Department of Pulmonology at the Piquet Carneiro Policlinic, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

ORCID iDs

Marcela Pinto Venâncio Lourenço da Silva

Agnaldo José Lopes

Ethical statement

Author contributions

Conceptualization: M.P.V.L.S., A.S.D., W.C., A.P.S., A.J.L.; Data curation: P.V.L.S.P.; I.M.P.P.F.; L.S.L.; Formal analysis: M.P.V.L.S., A.J.L.; Funding acquisition: A.J.L.; Investigation: M.P.V.L.S., A.J.L.; Methodology: M.P.V.L.S., A.S.D., W.C., A.P.S., A.J.L.; Resources: M.P.V.L.S., A.J.L.; Supervision: M.P.V.L.S.; Writing – original draft: A.J.L.; Writing – review & editing: M.P.V.L.S., P.V.L.S.P.; I.M.P.P.F.; L.S.L.; A.S.D., W.C., A.P.S., A.J.L.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Grant numbers #301967/2022-9 and #401633/2023-3), Brazil; the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ; Grant number #E-26/200.929/2022), Brazil, and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Finance Code 001), Brazil.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

Data will be made available on request.*

References

Malefane

Maarman

. Post-tuberculosis lung disease and inflammatory role players: can we characterise the myriad inflammatory pathways involved to gain a better understanding? Chem Biol Interact 2024; 387: 110817.

Seo

Kim

, et al. Long term management of people with post-tuberculosis lung disease. Korean J Intern Med 2024; 39: 7–24.

World Health Organization . Global tuberculosis report 2022. WHO, 2022. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2022 (accessed 15 January 2025).

Mpagama

Msaji

Kaswaga

, et al. The burden and determinants of post-TB lung disease. Int J Tubercul Lung Dis 2021; 25: 846–853.

Menzies

Quaife

Allwood

, et al. Lifetime burden of disease due to incident tuberculosis:a global reappraisal including post-tuberculosis sequelae. Lancet Global Health 2021; 9: e1679–e1687.

Romanowski

Baumann

Basham

, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19: 1129–1137.

Yadav

Rawal

. Understanding the spectrum and management of post-tuberculosis lung disease: a comprehensive review. Cureus 2024; 16: e63420.

Ravimohan

Kornfeld

Weissman

, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018; 27: 170077.

Mkoko

Naidoo

Mbanga

, et al. Chronic lung disease and a history of tuberculosis (post-tuberculosis lung disease): clinical features and in-hospital outcomes in a resource-limited setting with a high HIV burden. S Afr Med J 2019; 109: 169–173.

10.

Hunter

. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis 2011; 91: 497–509.

11.

Kim

Park

, et al. Bronchiectasis in active tuberculosis. Acta Radiol 2013; 54(4): 412–417.

12.

Pasipanodya

Miller

Vecino

, et al. Pulmonary impairment after tuberculosis. Chest 2007; 131: 1817–1824.

13.

Migliori

Marx

Ambrosino

, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tubercul Lung Dis 2021; 25: 797–813.

14.

Allwood

Maasdorp

Kim

, et al. Transition from restrictive to obstructive lung function impairment during treatment and follow-up of active tuberculosis. Int J Chronic Obstr Pulm Dis 2020; 15: 1039–1047.

15.

van der Zalm

Jongen

Swanepoel

, et al. Impaired lung function in adolescents with pulmonary tuberculosis during treatment and following treatment completion. eClinicalMedicine 2024; 67: 102406.

16.

Park

Lee

, et al. Diagnosis and evaluation of small airway disease and COPD using impulse oscillometry. Sci Rep 2024; 14: 28030.

17.

Silva

Santos

Visca

, et al. Brazilian Thoracic Association recommendations for the management of post-tuberculosis lung disease. J Bras Pneumol 2024; 49: e20230269.

18.

American Thoracic Society American College of Chest Physicians . ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211–277.

19.

Curry

Wout

EVT

Maasdorp

, et al. Correlation between lung function tests and peak oxygen consumption in post-TB lung disease. Int J Tubercul Lung Dis 2022; 26: 259–267.

20.

Yarbrough

Miller

Zulu

, et al. Post-tuberculosis lung disease: addressing the policy gap. PLOS Glob Public Health 2024; 4: e0003560.

21.

Allwood

van der Zalm

Amaral

AFS

, et al. Post-tuberculosis lung health: perspectives from the first international symposium. Int J Tubercul Lung Dis 2020; 24: 820–828.

22.

Cesilia

Rinawan

Santoso

, et al. Post-TB sequelae in adolescent pulmonary TB survivors. IJTLD Open 2025; 2: 19–25.

23.

Levett

DZH

Jack

Swart

, et al. Perioperative cardiopulmonary exercise testing (CPET): consensus clinical guidelines on indications, organization, conduct, and physiological interpretation. Br J Anaesth 2018; 120: 484–500.

24.

Fleck

Louzada

Xavier

, et al. Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref. Rev Saude Publica 2000; 34: 178–183.

25.

Kovelis

Segretti

Probst

, et al. Validation of the modified pulmonary functional status and dyspnea questionnaire and the medical research council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol 2008; 34: 1008–1018.

26.

King

Bates

Berger

, et al. Technical standards for respiratory oscillometry. Eur Respir J 2020; 55: 1900753.

27.

Butzko

Sotolongo

Helmer

, et al. Forced oscillation technique in veterans with preserved spirometry and chronic respiratory symptoms. Respir Physiol Neurobiol 2019; 260: 8–16.

28.

Chaiwong

Namwongprom

Liwsrisakun

, et al. Diagnostic ability of impulse oscillometry in diagnosis of chronic obstructive pulmonary disease. COPD 2020; 17: 635–646.

29.

Graham

Steenbruggen

Miller

, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med 2019; 200: e70–e88.

30.

Pereira

CAC

Sato

Rodrigues

. Novos valores de referência para espirometria forçada em brasileiros adultos de raça branca. J Bras Pneumol 2007; 33: 397–406.

31.

Lopes

Camilo

De Menezes

SLS

, et al. Impact of different etiologies of bronchiectasis on the pulmonary function tests. Clin Med Res 2015; 13: 12–19.

32.

Nieman

Lasasso

Austin

, et al. Validation of Cosmed's FitMate in measuring exercise metabolism. Res Sports Med 2007; 15(1): 67–75.

33.

Mezzani

. Cardiopulmonary exercise testing: basics of methodology and measurements. Ann Am Thorac Soc 2017; 14(Supplement 1): S3–S11.

34.

Neder

Nery

Castelo

, et al. Prediction of metabolic and cardiopulmonary responses to maximum cycle ergometry: a randomised study. Eur Respir J 1999; 14: 1304–1313.

35.

Schober

Boer

Schwarte

. Correlation coefficients: appropriate use and interpretation. Anesth Analg 2018; 126: 1763–1768.

36.

Kang

. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof 2021; 18: 17.

37.

Dourado

Nishiaka

Simões

MSMP

, et al. Classification of cardiorespiratory fitness using the six-minute walk test in adults: comparison with cardiopulmonary exercise testing. Pulmonology 2021; 27: 500–508.

38.

Baik

Maenetje

Schramm

, et al. Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: a prospective cohort study. BMC Pulm Med 2023; 23: 53.

39.

Radtke

Crook

Kaltsakas

, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. Eur Respir Rev 2019; 28: 180101.

40.

Ekström

Lewthwaite

, et al. Normative reference equations for breathlessness intensity during incremental cardiopulmonary cycle exercise testing. Ann Am Thorac Soc 2024; 21: 56–67.

41.

Silva

Freitas

Guimarães

, et al. Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. J Bras Pneumol 2022; 48: e20210515.

42.

Kamenar

Hossen

Gupte

, et al. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax 2022; 77: 1088–1097.

43.

Feldman

Theron

Cholo

, et al. Cigarette smoking as a risk factor for tuberculosis in adults: epidemiology and aspects of disease pathogenesis. Pathogens 2024; 13: 151.

44.

Xing

Sun

Janssens

, et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey. Thorax 2023; 78: 274–280.

45.

Amaral

Coton

Kato

, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J 2015; 46: 1104–1112.

46.

Guan

W-J

Gao

Y-H

, et al. Impulse oscillometry in adults with bronchiectasis. Ann Am Thorac Soc 2015; 12: 657–665.

47.

Long

Maycher

Dhar

, et al. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 1998; 113: 933–943.

48.

Singh

Allwood

Chiyaka

, et al. Immunologic and imaging signatures in post tuberculosis lung disease. Tuberculosis 2022; 136: 102244.

49.

Meghji

Simpson

Squire

, et al. A systematic review of the prevalence and pattern of imaging defined post-TB lung disease. PLoS One 2016; 11: e0161176.

50.

Kodical

Roy

Shetty

, et al. Exploring factors influencing the health-related quality of life of tuberculosis patients: a WHOQOL-BREF-based study. Monaldi Arch Chest Dis 2024; 95: 2913.

51.

Sharma

Yadav

Sharma

, et al. Quality of life of multi drug resistant tuberculosis patients: a study of north India. Acta Med Iran 2014; 52: 448–453.

52.

Chen

, et al. The relationship among social support experienced stigma, psychological distress, and quality of life among tuberculosis patients in China. Sci Rep 2021; 11: 24236.

53.

Sawada

Tanaka

Funakoshi

, et al. Five year prospective study on blood pressure and maximal oxygen uptake. Clin Exp Pharmacol Physiol 1993; 20: 483–487.

54.

Magrani

Pompeu

FAMS

. Equations for predicting aerobic power (VO(₂)) of young Brazilian adults. Arq Bras Cardiol 2010; 94: 763–770.

55.

Almeida

AEM

Stefani

Nascimento

, et al. An equation for the prediction of oxygen consumption in a Brazilian population. Arq Bras Cardiol 2014; 103: 299–307.

56.

Báez-Saldaña

López-Arteaga

Bizarrón-Muro

, et al. A novel scoring system to measure radiographic abnormalities and related spirometric values in cured pulmonary tuberculosis. PLoS One 2013; 8: e78926.

Correlations between exercise oxygen consumption,lung function,image findings,and quality of life in adults with post-tuberculosis lung disease

Abstract

Keywords

Introduction

Materials and methods

Participants

Instruments and measurements

Statistical analysis

Results

Discussion

Conclusion

Footnotes

Acknowledgements

ORCID iDs

Ethical statement

Author contributions

Funding

Declaration of conflicting interests

Data Availability Statement

References